Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dror Tobi

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Endocrinology|June 13, 2022
Three-Dimensional Modeling of Thyroid Hormone Metabolites Binding to the Cancer-Relevant αvβ3 Integrin: <i>In-Silico</i> Based StudyDror Tobi, Eilon Krashin, Paul J Davis, et al.
Applied Bioinformatics|February 8, 2005
A sequence alignment-independent method for protein classificationJohn K Vries, Rajan Munshi, Dror Tobi, et al.
Pharmaceutics|July 27, 2022
Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug DeliveryOlga Furman, Alisa Zaporozhets, Dror Tobi, et al.
Oncotarget|October 22, 2016
Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanomaBoris Redko, Helena Tuchinsky, Tamar Segal, et al.
Bioorganic & Medicinal Chemistry|June 14, 2024
Synthesis and anticancer properties of novel dolastatin 10 analogs featuring five-membered heterocyclic rings with a linkable group at the C-terminusAkash Panja, Vipin Sharma, Pousali Mitra, et al.
Molecular Pharmacology|July 3, 2004
Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphataseMarni Brisson, Theresa Nguyen, Andreas Vogt, et al.
Oncotarget|August 25, 2016
Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma modelsShiri Yacobovich, Lena Tuchinsky, Michael Kirby, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 8, 2026
Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRCShachar Ayali, Akash Panja, Pousali Mitra, et al.
Scientific Reports|March 28, 2025
Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemiaDipak Walunj, Katarina Egarmina, Adi Zipin-Roitman, et al.
The Journal of Biological Chemistry|October 23, 2003
Sequence-based design of kinase inhibitors applicable for therapeutics and target identificationMasha Y Niv, Hila Rubin, Jacob Cohen, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Endocrinology|June 13, 2022
Three-Dimensional Modeling of Thyroid Hormone Metabolites Binding to the Cancer-Relevant αvβ3 Integrin: <i>In-Silico</i> Based StudyDror Tobi, Eilon Krashin, Paul J Davis, et al.
Applied Bioinformatics|February 8, 2005
A sequence alignment-independent method for protein classificationJohn K Vries, Rajan Munshi, Dror Tobi, et al.
Pharmaceutics|July 27, 2022
Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug DeliveryOlga Furman, Alisa Zaporozhets, Dror Tobi, et al.
Oncotarget|October 22, 2016
Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanomaBoris Redko, Helena Tuchinsky, Tamar Segal, et al.
Bioorganic & Medicinal Chemistry|June 14, 2024
Synthesis and anticancer properties of novel dolastatin 10 analogs featuring five-membered heterocyclic rings with a linkable group at the C-terminusAkash Panja, Vipin Sharma, Pousali Mitra, et al.
Molecular Pharmacology|July 3, 2004
Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphataseMarni Brisson, Theresa Nguyen, Andreas Vogt, et al.
Oncotarget|August 25, 2016
Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma modelsShiri Yacobovich, Lena Tuchinsky, Michael Kirby, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 8, 2026
Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRCShachar Ayali, Akash Panja, Pousali Mitra, et al.
Scientific Reports|March 28, 2025
Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemiaDipak Walunj, Katarina Egarmina, Adi Zipin-Roitman, et al.
The Journal of Biological Chemistry|October 23, 2003
Sequence-based design of kinase inhibitors applicable for therapeutics and target identificationMasha Y Niv, Hila Rubin, Jacob Cohen, et al.
Pageof 3